Brevilin A

Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC50= 10.6 μM) . Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy[1][2].

Product Specifications

CAS Number

[16503-32-5]

UNSPSC

12352005

Hazard Statement

H317

Target

Apoptosis; Autophagy; JAK; STAT

Type

Natural Products

Related Pathways

Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brevilin-a.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C=C(C)\C(O[C@H]1[C@@]([C@@H]2C)([H])[C@@](OC2=O)([H])C[C@@H](C)[C@@]3([H])[C@]1(C(C=C3)=O)C)=O

Molecular Formula

C20H26O5

Molecular Weight

346.42

Precautions

H317

References & Citations

[1]Chen X, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013 May 21;8 (5) :e63697.|[2]You P, et al. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. Biomed Pharmacother. 2018 Feb;98:619-625.